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Setting the Stage for ARV-based Prevention for
Women: A Snapshot of the Zimbabwean Context

Zimbabwe has seen a substantial shift in the
HIV landscape in the last decade, with prevalence among adults aged 15 and above
decreasing from an estimated 24.3 percent
of the population in 2001 to less than 15
percent in 2012 (UNAIDS 2013). The reduction in the number of people living with HIV
(PLHIV) has been attributed to scaling up
both treatment and prevention (Hargrove et
al. 2011). In particular, increased emphasis
on behavioural interventions, such as condom use and reduction of sexual partners
has been credited with nearly halving the
number of new infections annually between
2001 and 2012 (Gregson et al. 2010; Halperin et al. 2011). Yet, despite this progress,
many people, especially women, are still at
high risk and efforts to identify and implement additional HIV prevention options
remain critical.
These developments have taken place
against the backdrop of unprecedented
socio-economic decline in Zimbabwe, which
has significantly compromised the avail-

ability, use, and quality of health and social
services. As a result, coverage of most basic
health services has decreased, leading to
stagnation or deterioration of some health
indicators.
Despite the political and economic situation
in Zimbabwe, clinical research is of the highest caliber, and Zimbabwe has participated
in many large-scale HIV prevention trials,
including safety and effectiveness studies
of tenofovir gel and several other candidate
microbicides. Topically applied microbicides
are under development as a method women
could use to reduce their risk of HIV and possibly other sexually transmitted infections.
Tenofovir gel has been shown to reduce the
risk of HIV acquisition by 39 percent in the
CAPRISA 004 trial in South Africa, the first
candidate microbicide to show effectiveness
in a clinical trial (Abdool Karim et al. 2010).
The confirmatory FACTS 001 trial of tenofovir
gel is now underway in South Africa, with
results expected in 2014.

Background on this Brief
Given the urgent need for HIV prevention options for
women, a number of projects are underway to prepare
for introduction of tenofovir gel should it be shown effective. One of these is a toolkit developed by the Population Council to assist policymakers and programme
managers in identifying the most strategic opportunities for introducing tenofovir gel. The toolkit includes
three related components: a landscape analysis; a
discussion guide for key opinion leader interviews; and
a programme planning tool. The landscape analysis,
summarised in this programme brief, includes a review
of the epidemiologic context of the HIV epidemic along
with a scan of key policies and programmes related
to HIV and most relevant to tenofovir gel. It draws on
a desk review of peer-reviewed and grey literature as
well as interviews with key decision makers. The full report and annexes are available at www.popcouncil.org.

HIV in Zimbabwe

common source of HIV in the country. Both modes of
transmission remain pressing public health challenges
despite considerable attention to address them.
In fact, Zimbabwe is on track to achieve the Millennium
Development Goal of halting and reversing the spread
of HIV/AIDS by 2015 due both to high AIDS mortality rates and to changes in sexual behaviour. These
behaviour changes, such as increased use of condoms
in casual relationships and partner reduction, have
resulted largely from personal experience with AIDS
mortality (Gregson et al. 2010; Halperin et al. 2011).
Although Zimbabwe is one of the few countries in the
region to have experienced a substantial reduction in
HIV prevalence, HIV/AIDS continues to be a significant
contributor to the overall burden of disease.

Women, Girls, and HIV
HIV prevalence is higher among women than men
across all age groups, except those 40–49 years old
(see Figure 1). In particular, prevalence in some younger age groups is almost twice as high among women
as among men (UNAIDS 2013). Sex with high-risk
partners and multiple partners continues to be strongly associated with risk of HIV infection among women.
Young women’s risk is driven by a complex array of
biological, social, economic and structural factors, including gender-based violence and men’s alcohol use.

Zimbabwe has a generalised,
heterosexually driven HIV epidemic;
heterosexual transmission accounts
for over 90 percent of HIV infections in the country (UNAIDS 2012).
Vertical transmission, where HIV
is passed from a mother to child
during pregnancy, childbirth, and/or
breastfeeding, is the second most
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Zimbabwe, with an estimated population of 12.7
million people, is among the countries in sub-Saharan
Africa most affected by the HIV epidemic. In 2012, a
total of 1.2 million adults and children were living with
HIV and AIDS. This includes an estimated 14.7 percent
of the population 15–49 years old, with an estimated
69,000 new infections in 2012
(UNAIDS 2013). HIV in Zimbabwe is
characterised by variation among
Figure 1 HIV prevalence by age and gender
and within provinces at the local
30
and district levels. Many HIV treatment and prevention programmes
25
have targeted these defined geographic areas, and such a focus
20
may be appropriate for ultimate
delivery of tenofovir gel.
15
10
5
0

15–19

20–24

25–29

30–34

Women

35–39

40–44

45–49

Men

Source: ZIMSTAT and ICF International. 2012. Demographic and Health Survey [DHS]

2 ı Setting the Stage for ARV-Based Prevention for Women: A Snapshot of the Zimbabwean Context

As in many other settings, gender-based violence is
associated with HIV in Zimbabwe. The 2010–11 ZDHS
(ZIMSTAT/ICF International 2012) found that sexual
and physical violence occurred in intimate and other
relationships across culture and class. Thirty percent
of women aged 15–49 reported having experienced
physical violence since the age of 15. The most common perpetrator was a current or former husband or
partner. Married women who had experienced physical
and/or sexual violence were significantly more likely
to be HIV positive than those who had not experienced
any physical or sexual violence (Nyamayemombe et al.
2010).
Men’s alcohol use has also been correlated with increasing women’s risk of HIV; consumption of alcohol
is associated with men having higher numbers of
sexual partners, and higher rates of HIV infection (Fraser et al. 2011). In Zimbabwe, research on the role of
beer halls in the HIV epidemic shows that going to beer
halls was associated with concurrent sexual partnerships (Lewis et al. 2005) and that men who reported
having sex while drunk were more likely to report
unprotected sex with casual partners and when paying
for sex (Fraser et al. 2011).

Most at-risk Populations
Data on prevalence and incidence are scarce among
those identified by UNAIDS as the most at-risk populations—men who have sex with men (MSM), sex workers, and injecting drug users (IDUs). Little information
is available about the overall HIV prevalence in these
populations, and to date no systematic size estimations have been conducted. Sex work and homosexuality are both illegal in Zimbabwe, and this, combined
with definitional and measurement problems, means
that both are likely to be underreported. The lack of
legal status and protections for sex workers and MSM
presents obstacles to effective HIV prevention, treatment, care and support in these populations. Despite
these challenges, some groups focused on HIV prevention have identified “hot spots” among these groups
and provided services for sex workers and MSM, as
well as IDUs.

Reproductive Health Indicators
Contraceptive Prevalence
According to the 2010–2011 Zimbabwe Demographic Health Survey (ZDHS), 59 percent of all married
women surveyed reported using family planning,
nearly all using a modern method. Oral contraceptive pills were the most common method, used
by 41 percent of women, while use of injectables,
male and female condoms, implants and sterilization was less common (ZIMSTAT/ICF International
2012). Given the relatively high overall use of family
planning programmes, efforts to deliver tenofovir gel
could build on this system, including the logistics
for product storage and distribution of contraceptive
commodities.

Sexually Transmitted Infections (STIs)
HIV infection is clustered among people with a history
of STIs, especially genital ulcer disease. According
to the 2010–2011 ZDHS, 10 percent of women and
seven percent of men had had an STI or STI symptoms
in the year preceding the survey. Of those, 47 percent
of women and 48 percent of men sought advice or
treatment from a clinic, hospital, private doctor, or
other health professionals (ZIMSTAT/ICF International
2012). STI prevention is now part of HIV prevention
programmes in Zimbabwe and is linked to other programmes including antenatal care (ANC), sexual and
reproductive health, HIV testing and counselling (HTC),
prevention of mother-to-child transmission (PMTCT),
antiretroviral treatment (ART) and condom promotion
(UNAIDS 2012).

Maternal Health Care
The 2010–11 ZDHS shows that 90 percent of women
who gave birth in the previous five years received antenatal care from a trained health professional for their
last birth. The majority of women in Zimbabwe deliver
in a health facility with a trained attendant; 65 percent
of births were delivered in a health facility.
A cohort study showed that HIV incidence was very
high during the first nine months after childbirth
(5.7/100 women-years-at-risk). Women who knew
that their partners had other sexual partners were
about four times more likely to acquire HIV (Munjoma
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et al. 2010). These data suggest that the post-partum
period may be a particularly important time to reach
women with new HIV prevention technologies or strategies, and that post-partum or infant care programmes
might be considered as potential venues for pilot
programmes. The relatively high proportion of births
delivered in a health facility may provide an opportunity to encourage women to come for follow-up services,
including making HIV prevention methods available.

Policy Environment
Zimbabwe’s policies, strategies and programmes
have both anticipated and responded to established
priorities and emerging approaches to HIV prevention.
Zimbabwe’s national response to the HIV epidemic has
been guided by the National Policy on HIV and AIDS,
which was adopted in December 1999 through an act
of Parliament. The current Zimbabwe National HIV and
AIDS Strategic Plan (ZNASP) 2011–2015 is driven by
the National AIDS Council (NAC), and its implementation is spearheaded by the Ministry of Health (MoH). It
is supported by the National AIDS Trust Fund (NATF), a
three percent levy on personal and corporate income.
Its priorities are:
●● Prevention of new HIV infections in adults and children, aiming to reduce the rate of annual infections
by 50 percent by 2015;
●● Reduction of mortality among people living with HIV,
aiming to reduce annual AIDS deaths by 38 percent
by 2015.
Complementing and building on these overall policies
are various sector-level policies, strategies and workplans, many of which emphasise the importance of
prevention in Zimbabwe’s response to HIV. Specific
guidelines covering the range of standard and emerging biomedical interventions are based on local evidence as well as international standards. Zimbabwe is
also increasingly looking at policies to address broader
structural factors that drive HIV risk. For example,
the US Centers for Disease Control and Prevention
is assisting Zimbabwe to develop an alcohol policy,
indicating recognition of the role that alcohol use
plays in driving risky behavior and HIV incidence. This

policy environment reflects the country’s commitment
to fulfilling a number of international and regional
obligations related to HIV, and a degree of openness to
new prevention approaches even in the face of considerable economic constraints.
Despite significant political and economic uncertainty,
Zimbabwe has relatively well-developed policy and
regulatory environments, along with technical experts
who have played pivotal roles in a number of trials of
microbicides and other female-initiated prevention
technologies. Zimbabwe’s commitment to and success
with introducing and making available the female condom is noteworthy (see below). This policy and scientific expertise can be brought to bear on a thorough
analysis of how tenofovir gel can address the specific
prevention needs of the country.

Regulatory Processes
Several entities will need to be involved in the regulatory process in Zimbabwe, should tenofovir gel be proven
efficacious. The Medicines Control Authority of Zimbabwe (MCAZ) is the key regulatory body responsible for
product licensure, while the MoH oversees overall HIV
prevention programmes. The National Medicines and
Therapeutics Policy Advisory Committee (NMTPAC) has
the mandate to advise the MoH on the introduction of
new drugs into Zimbabwe. Ad hoc expert committees
are convened to review data and make a recommendation to NMTPAC as to whether or not a new drug
should be introduced. Then the NMTPAC makes a recommendation to the MoH, which ultimately determines
whether a drug will be made available in Zimbabwe.
Licensure by MCAZ is an essential step before the MoH
draws up guidelines for use and distribution. Given
MCAZ’s central role in reviewing clinical trial data it
may be useful to involve this group as soon as possible
to speed the approval process in Zimbabwe.

Programmes and Strategy
The public health system in Zimbabwe has a number
of programmes that could potentially serve as the setting for introducing tenofovir gel. Some key elements of
these programmes are summarised below.
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Condoms

HIV Testing

Male condoms

Overall testing availability and use is relatively high
in Zimbabwe. HIV testing and counselling (HTC) has
evolved to a nationwide programme of provider-initiated testing and counselling (PICT). HTC services are
provided through mobile outreach, workplace programmes, and family planning clinics. These services
are also available at Level 1 health facilities, a large
proportion of which offer PICT and voluntary counselling and testing (VCT). The 2011 ZDHS reported
generally uniform coverage rates (79–82 percent) of
HIV testing among women across all age groups.

Zimbabwe has developed a strong infrastructure for
condom distribution from the national to community
levels, including social marketing initiatives. In 2008,
95.5 million male condoms were distributed, although
the current 2011–2015 strategic plan’s annual target
of 150 million has not yet been met. Reported condom
use is relatively high during high-risk sex (47 percent
of females; 71 percent of males), but condom use with
regular partners remains low (4 percent of females, 8
percent of males) (Fraser et al. 2011).

Female condoms
Female condom promotion and distribution is spearheaded by the MoH, the Zimbabwe National Family
Planning Council (ZNFPC) and Population Services
International (PSI). Female condoms are sold through
pharmacies and hair salons, as well as barber shops,
sex worker networks, and support groups for PLHIV. Female condom distribution has been relatively successful in Zimbabwe. For example, between 2004–2007
Care brand female condom distribution increased
by 150 percent and public sector distribution tripled
(CHANGE 2009). Although delivery of tenofovir gel
will be different, involving the formal health system to
manage testing, monitoring and other issues, experience with the female condom can help inform how programmes in Zimbabwe and elsewhere can successfully
reach women with a new female-initiated prevention
technology.

PMTCT
Provision of PMTCT services in Zimbabwe has continued to improve. In 2009, 56 percent of pregnant women who tested positive for HIV benefitted from antiretroviral (ARV) prophylaxis, although HIV testing reached
only 46 percent of pregnant women (UNICEF 2010).
At the end of 2009, 55 percent of ANC facilities were
registered to offer comprehensive PMTCT services and
the rest were providing a minimum package of PMTCT
services. More efficacious treatment regimens for
mothers were piloted and the PMTCT treatment guidelines were amended in 2010 (Ciaranello et al. 2011).

With the advent of the WHO guidelines suggesting initiating treatment at a CD4 count of 350, the NAC has
encouraged people to be re-tested so that they may be
put on ARV treatment (NAC 2013). While data on
re-testing is minimal, programme experience and estimates suggest an increase in re-testing among people
who have previously tested HIV negative. This has
been attributed to increased access to ART medication. Further analysis of these clients and programmes
may provide insights for structuring the testing and
re-testing that will be needed for ARV-based prevention
implementation. While it is possible that adding tenofovir gel may create a burden for the already taxed HIV
testing system, it would also give providers something
to offer to women who test negative, and potentially
attract women to HIV testing services.

Financing
Both domestic and international sources of support
have funded Zimbabwe’s HIV and AIDS response. The
Government of Zimbabwe’s main source of domestic
funding is generated through the NATF. The Ministry
of Finance channels these funds directly to the NAC.
According to the UNAIDS 2012 country report, NATF
contributed approximately US$5 million in 2009,
US$20.5 million in 2010, and US$26.5 million in 2011
towards HIV programmes. Approximately 50 percent of
these funds were used for ARV procurement, and the
remainder supported other HIV programmes, administration and coordination (UNAIDS 2012).
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International contributions for HIV and AIDS also
increased sharply from approximately US$54 million in
2009 to US$114 million in 2010, attributable in part
to monies from Global Fund Round 8 Phase 1 funds
(UNAIDS 2012). During this time, the proportion of
total HIV/AIDS spending for prevention decreased from
39 percent in 2006 to 22 percent in 2009, reflecting
the shift of resources and programme emphasis to
treatment roll-out. Of the 2009 expenditure for prevention, over 40 percent was spent on PMTCT activities;
about 17 percent on communication for social and
behaviour change; and about 15 percent on VCT.
Given that the challenging economic climate in Zimbabwe will likely remain a significant barrier to government financing for tenofovir gel introduction, external
agencies will be needed to help support the cost of
both programming and subsidizing product, at least
initially.

Looking Ahead
Zimbabwe can build on its policy and scientific capacity to determine whether tenofovir gel offers added
benefits relative to costs within the evolving context
of prevention interventions, including relatively new
approaches such as treatment as prevention, medical
male circumcision and oral pre-exposure prophylaxis.
If Zimbabwe determines that tenofovir gel would be a
useful addition to its HIV prevention programme, pilot
demonstration projects will be critical to determine the
most strategic entry points for tenofovir gel introduction. These may include services for family planning,
and HIV testing and re-testing, as well as programmes
for post-partum women and sero-discordant couples.
Such projects would assess the overall feasibility of
introduction as well as identify ways to address specific
operational issues. Zimbabwe’s momentum in reducing HIV, experience with new technologies and clinical
trials, as well as its capacity for operations research,
makes it a conducive setting to design and conduct
such demonstration projects, and initial planning and
protocol development can begin now.

6 ı Setting the Stage for ARV-Based Prevention for Women: A Snapshot of the Zimbabwean Context

REFERENCES

Nyamayemombe, C. et al. 2010. “The association between violence against women and HIV: Evidence from
a national population-based survey in Zimbabwe,”
Zimbabwe Working Papers, No.4. Calverton, Maryland,
USA: ICF Macro.

Abdool Karim, Q. et al. 2010. “Effectiveness and
safety of tenofovir gel, an antiretroviral microbicide,
for the prevention of HIV infection in women,” Science 329(5996): 1168–1174. DOI:10.1126/science.1193748.

UNAIDS. 2012. “Global AIDS response progress
report 2012. Follow up to the 2011 political declaration on HIV/AIDS: intensifying our efforts to eliminate HIV/AIDS: Zimbabwe country report.” Geneva:
UNAIDS. Available at: http://www.unaids.org/en/
dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_ZW_Narrative_Report.pdf

Center for Health and Gender Equity (CHANGE). 2009.
“Female condoms: lessons from Zimbabwe,” Country
profile. Washingtin, DC: CHANGE. Available at: http://
www.genderhealth.org/files/uploads/change/publications/zimbabwecountryprofile.pdf. Accessed 10
February 2014.

UNAIDS. 2013. “Global report: UNAIDS report on the
global AIDS epidemic 2013.” Geneva: UNAIDS. Revised
and reissued, November 2013.

Ciaranello, A. L. et al. 2011. “WHO 2010 guidelines
for prevention of mother-to-child HIV transmission in
Zimbabwe: modeling clinical outcomes in infants and
mothers,” PLoS One 6(6): e20224. doi: 10.1371/journal.pone.0020224.
Fraser, N. et al. 2011. Zimbabwe Analysis of HIV Epidemic, Response, and Modes of Transmission. Harare:
Zimbabwe National AIDS Council.
Gregson, S. et al. 2010. “HIV decline in Zimbabwe due
to reductions in risky sex? Evidence from a comprehensive epidemiological review,” International Journal
of Epidemiology 39(5): 1311–1323.

UNICEF. 2010. “Countdown to Zero: Elimination of New
HIV Infections among Children by 2015 and Keeping
their Mothers Alive.” Available at: http://www.childinfo.
org/hiv_aids_factsheets.html. Accessed 10 February
2014.
Zimbabwe National Statistics Agency (ZIMSTAT) and
ICF International. 2012. Zimbabwe Demographic and
Health Survey [DHS] 2010–11. Calverton, Maryland,
USA: ZIMSTAT and ICF International.

Halperin, D. T. et al. 2011. “A surprising prevention
success: Why did the HIV epidemic decline in Zimbabwe?,” PLoS Medicine 8(2): e1000414. DOI: 10.1371/
journal.pmed.1000414
Hargrove, J. W. et al. 2011. “Declining HIV prevalence and incidence in perinatal women in Harare,
Zimbabwe,” Epidemics 3(2):88–94. doi: 10.1016/j.
epidem.2011.02.004.
Lewis, J. J. et al. 2005. “Beer halls as a focus for HIV
prevention activities in rural Zimbabwe,” Sexually
Transmitted Diseases 32:364–369.
Munjoma, M. W. et al. 2010. “The incidence of HIV
among women recruited during late pregnancy and
followed up for six years after childbirth in Zimbabwe,”
BMC Public Health 10:668. doi: 10.1186/1471-245810-668.
National AIDS Council (NAC). 2013. “Zimbabwe to
adopt new World Health Organization antiretroviral therapy guidelines.” Harare: Zimbabwe NAC.
Available at: http://www.nac.org.zw/news/zimbabwe-adopt-new-world-health-organization-antiretroviral-therapy-guidelines. Accessed 24 January 2014.
Setting the Stage for ARV-Based Prevention for Women: A Snapshot of the Zimbabwean Context ı 7

This analysis and brief were made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents of this report are the sole responsibility of the Population Council and do not necessarily reflect
the views of USAID or the United States Government.

The Population Council confronts critical health and development issues—from stopping the spread of HIV to improving
reproductive health and ensuring that young people lead full and productive lives. Through biomedical, social science and
public health research in about 50 countries, the Council works with our partners to deliver solutions that lead to more effective policies, programs, and technologies to improve lives worldwide. Established in 1952 and headquartered in New York, the Council is a nongovernmental,
nonprofit organization with an international board of trustees.
Suggested citation: Population Council. 2014. “Setting the stage for ARV-based prevention for women: a snapshot of the Zimbabwean context,” Program Brief.
Johannesburg and New York: Population Council.

www.popcouncil.org
Published February 2014. © 2014 The Population Council, Inc.

